Page 1 of 1

Fampridin-SR Phase 3 Trial

Posted: Thu Jun 30, 2005 7:22 am
by Sharon
Acorda Therapeutics Initiates Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis. See website http://www.acorda.com/investors_news_detail.asp?id=76
The primary outcome measurement for the study will be an improvement in walking ability; secondary outcomes will include measurements of leg strength and muscle spasticity.
Individuals who are interested in learning about study enrollment can call 877-716-2518.

Hopefully, this treatment will meet the measurements and we will finally have something which will help us to improve mobility. Also, as important, a treatment for spinal cord injury.

Sharon